Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

PURPOSE: Standard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may be beneficial, but robust data to support this are lacking. The efficacy and safety of the addition of capecitabine into the TNBC adjuvant treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junjie, Yu, Keda, Pang, Da, Wang, Changqin, Jiang, Jun, Yang, Suisheng, Liu, Yunjiang, Fu, Peifen, Sheng, Yuan, Zhang, Guojun, Cao, Yali, He, Qi, Cui, Shude, Wang, Xijing, Ren, Guosheng, Li, Xinzheng, Yu, Shiyou, Liu, Pengxi, Qu, Xiang, Tang, Jinhai, Wang, Ouchen, Fan, Zhimin, Jiang, Guoqin, Zhang, Jin, Wang, Jiandong, Zhang, Hongwei, Wang, Shui, Zhang, Jianguo, Jin, Feng, Rao, Nanyan, Ma, Binlin, He, Pingqing, Xu, Binghe, Zhuang, Zhigang, Wang, Jianfeng, Sun, Qiang, Guo, Xiaofeng, Mo, Miao, Shao, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255982/
https://www.ncbi.nlm.nih.gov/pubmed/32275467
http://dx.doi.org/10.1200/JCO.19.02474

Ejemplares similares

Ejemplares similares